Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 studyArthur Bobin, Xavier Leleu, Cyrille Hulin et al.|Haematologica|2024Cited by 3
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette et al.|Blood Cancer Journal|2025Cited by 2
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette et al.|Research Square|2025Cited by 0